Skip to main content

Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T-cells specifically within tumours

Objective

Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just a
few years ago would have been considered untreatable. It thereby became apparent that one specific type of immune cell,
so called regulatory T-cells, critically hampers the efficacy of tumour immune-therapy. Tumours, however, attract and exploit
the immune-regulatory function of Tregs to dampen local immune responses and to induce local tolerance.
In recent years, inhibitors that directly target immune-suppressive mechanisms of T cells have found clinical application with
great success. The clinical application of these so called “check-point inhibitors”, however, is accompanied by severe side
effects in treated patients. Thus improvement of the efficacy of current immune-therapeutic treatments is a major unmet
need. This proposal will employ the newest developments in antibody design to target the next generation of biologics right
towards tumour-residential Tregs or directly into the tumour micro-environment itself. In this way we will be able to
specifically shift the local immune suppressive environment within tumours, while leaving tissue homeostasis in noncancerous
tissues unaffected, and thus diminish treatment associated side-effects.
The here proposed project combines the expertise of fundamental immunologist, tumour immunologists and cell biologists
with that of a life-science biotechnology company and that of experts in clinical cancer research to address this aspect. This
group will lead a training network that aims at educating a new generation of researchers, who will be able to bridge the
innovation gap between, on the one hand, early discoveries in tumour-immunology as well as in antibody technology and, on
the other hand, the efficient translation and clinical validations of these findings in patients.

Call for proposal

H2020-MSCA-ITN-2017
See other projects for this call

Funding Scheme

MSCA-ITN-EID - European Industrial Doctorates

Coordinator

UNIVERSIDAD DE NAVARRA
Address
Campus Universitario Edificio Central
31080 Pamplona
Spain
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 247 872,96

Participants (3)

THE UNIVERSITY OF EDINBURGH
United Kingdom
EU contribution
€ 273 287,88
Address
Old College, South Bridge
EH8 9YL Edinburgh
Activity type
Higher or Secondary Education Establishments
ADURO BIOTECH EUROPE BV
Netherlands
EU contribution
€ 510 748,56
Address
Kloosterstaat 9 Rx 1101
5349 AB Oss
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Spain
EU contribution
€ 247 872,96
Address
Avenida De Pio Xii 55
31008 Pamplona
Activity type
Research Organisations

Partners (2)

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
iOMEDICO AG
Germany
Address
Hanferstr. 28
79108 Freiburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)